Abstract:Significance: Reactive oxygen species (ROS) are generated during mitochondrial oxidative metabolism, and are tightly controlled through homeostatic mechanisms to maintain intracellular redox, regulating growth and proliferation in healthy cells. However, ROS production is perturbed in cancers where abnormal accumulation of ROS leads to oxidative stress and genomic instability, triggering oncogenic signaling pathways on one hand, while increasing oxidative damage and triggering ROS-dependent death signaling on the other. Recent Advances: Our review illuminates how critical interactions between ROS and oncogenic signaling, the tumor microenvironment, and DNA damage response (DDR) pathways have led to interest in ROS modulation as a means of enhancing existing anticancer strategies and developing new therapeutic opportunities. Critical Issues: ROS equilibrium exists via a delicate balance of pro-oxidant and antioxidant species within cells. "Antioxidant" approaches have been explored mainly in the form of chemoprevention, but there is insufficient evidence to advocate its routine application. More progress has been made via the "pro-oxidant" approach of targeting cancer vulnerabilities and inducing oxidative stress. Various therapeutic modalities have employed this approach, including direct ROS-inducing agents, chemotherapy, targeted therapies, DDR therapies, radiotherapy, and immunotherapy. Finally, emerging delivery systems such as "nanosensitizers" as radiotherapy enhancers are currently in development. Future Directions: While approaches designed to induce ROS have shown considerable promise in selectively targeting cancer cells and dealing with resistance to conventional therapies, most are still in early phases of development and challenges remain. Further research should endeavor to refine treatment strategies, optimize drug combinations, and identify predictive biomarkers of ROS-based cancer therapies.

Unravelling the relationship between macroautophagy and mitochondrial ROS in cancer therapy

Role of Autophagy in Cancer Development Via Mitochondrial Reactive Oxygen Species

Redox Regulation of Autophagy in Cancer: Mechanism, Prevention and Therapy

Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis

Mitochondrial Redox Signaling And Tumor Progression

Unraveling mitochondria‐targeting reactive oxygen species modulation and their implementations in cancer therapy by nanomaterials

Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy

The Role of Mitochondrial Dynamics and Mitophagy in Carcinogenesis, Metastasis and Therapy.

Reactive Oxygen Species Regulation of Autophagy in Cancer: Implications for Cancer Treatment.

Redox Signaling: Potential Arbitrator of Autophagy and Apoptosis in Therapeutic Response

Redox balance and autophagy regulation in cancer progression and their therapeutic perspective

ROS-mediated Autophagy and Its Role in the Pathogenesis

Key Autophagic Targets and Relevant Small-Molecule Compounds in Cancer Therapy.

Survival or Death: Disequilibrating the Oncogenic and Tumor Suppressive Autophagy in Cancer

Mitochondrial-Endoplasmic Reticulum Communication-Mediated Oxidative Stress and Autophagy

Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?

The Interplay between Autophagy and Mitochondria in Cancer

Autophagy, Metabolism, and Cancer

Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies

Interaction of autophagy with microRNAs and their potential therapeutic implications in human cancers.

Reactive Oxygen Species as a Link between Antioxidant Pathways and Autophagy